Alpharma API Hong Kong And Zhejiang Hisun Establish Joint Venture To Expand API Production
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - Alpharma API Hong Kong and Taizhou-based Zhejiang Hisun Pharmaceutical will establish a new joint venture facility to produce antibiotic Vancomycin and other APIs, Hisun announced on June 12
You may also be interested in...
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required.)